Retatrutide
Also known as: Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Who's worth your money for Retatrutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (95) of 7 scored sellers
$110 · 60mg · 99.5% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 10mg · 99.8% purity
Most tested
14 independent COAs on file
$130 · 15mg · 99.9% purity
Average price
$7.06/mg
Sellers
82
45-day trend
+3.5%
72 of 82 sellers have a current price· 65 stale hidden
Top Merit pick
🇺🇸 Prime Peptides95✓ verified at source · just now
$1.83/mg -74% vs avg$110
60mg
- 🇺🇸 Polaris Peptides90
✓ verified at source · just now
$8.67/mg +22.7% vs avg$130
15mg
- 🇨🇳 Reta Peptide83
✓ verified at source · just now
$13.50/mg +91.2% vs avg$135
10mg
- 🇺🇸 Blank Peptides81
✓ verified at source · just now
$3.50/mg -50.4% vs avg$105
30mg
- 🇺🇸 Bulk Peptides50
✓ verified at source · just now
$36.00/mg +409.9% vs avg$360
10mg
- 🇭🇰 Hkuppeptide49
✓ verified at source · just now
$1.00/mg -85.8% vs avg$10.00
10mg
- 🇭🇰 zztai Peptide Ltd42
✓ verified at source · just now
$9.33/mg +32.2% vs avg$280
30mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Retatrutide
Get one email when the market actually moves — no newsletter, no noise.
About Retatrutide
CAS
2381089-83-2
Molecular formula
C221H342N46O68
Sequence
YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS
Typical dose range
0.5–12 mg once weekly subcutaneous (Phase 2 titration; 2–8 mg most studied maintenance range)
Half-life
~6 days
COAs for Retatrutide
494 third-party tests across 54 vendors. Each card links to the full report.
For
Retatrutide
by Reta One Labs· batch RT120826
For
Retatrutide
by Sunrise Bioresearch· batch GLP320JUL26-01
For
Retatrutide
by Reta One Labs· batch RT150826
For
Retatrutide
by Reta One Labs· batch RT700726
For
Retatrutide
by Longeva· batch B-2026-RETA-60-002
For
Retatrutide
by Peptide Crafters· batch PC-J3-RT60
For
Retatrutide
by Peptide Plugs· batch 101-01-ZB
For
Retatrutide
by NG Peptide· batch RT20-09
For
Retatrutide
by Aspire Peptides· batch RT20-032026-1
For
Retatrutide
by Hydro Research Peptides· batch HR-2026-2836
For
Retatrutide
by Aspire Peptides· batch RT15-032026-1
For
Retatrutide
by Aspire Peptides· batch GLP-3R
For
Retatrutide
by Blank Peptides· batch B-1784041-P
For
Retatrutide
by Moglabs· batch RT103
For
Retatrutide
by Arcane Peptides· batch RT103
For
Retatrutide
by Arcane Peptides· batch RT103
For
Retatrutide
by Moglabs· batch RT103
For
Retatrutide
by EZ Peptides· batch EZP-3P1206222026-03
For
Retatrutide
by Peptide Partners· batch RTT2613
For
Retatrutide
by EZ Peptides· batch EZP-3P1206222026-03
For
Retatrutide
by Virtus Peptides· batch RT30-655
For
Retatrutide
by Virtus Peptides· batch RT10-655
For
Retatrutide
by Optima Supply· batch OS-2026-1258
For
Retatrutide
by Hydro Research Peptides· batch HR-2026-2051
23 citations indexed for Retatrutide
case-report · 2026
Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis
Growing public interest in incretin-based therapies for weight loss has been accompanied by increasing availability of research peptides purchasable online. Products may be used without medical assessment or counselling regarding adverse effects, sick-day management or appropriate follow-up.
Study · 2026
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
Aims To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D).
animal · 2026
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice
Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.
animal · 2026
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats
Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling.
review · 2026
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Introduction It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile.
rct · 2026
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Background Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications.